DFTX Definium Therapeutics Inc.

Price (delayed)

$24.64

Market cap

$2.69B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.49

Enterprise value

$2.47B

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is ...

Highlights
Definium Therapeutics's equity has increased by 25% YoY but it has decreased by 16% from the previous quarter
The company's EPS has shrunk by 162% YoY and by 21% QoQ
The debt has surged by 85% year-on-year

Key stats

What are the main financial stats of DFTX

DFTX stock price

How has the Definium Therapeutics stock price performed over time
Intraday
4.45%
1 week
4.94%
1 month
13.29%
1 year
222.09%
YTD
84.02%
QTD
30.37%

Financial performance

How have Definium Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$193.37M
Net income
-$237.54M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 70% year-on-year and by 16% since the previous quarter
The net income has declined by 29% since the previous quarter

Price vs fundamentals

How does DFTX's price correlate with its fundamentals

Growth

What is Definium Therapeutics's growth rate over time

Valuation

What is Definium Therapeutics stock price valuation
P/E
N/A
P/B
8.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has shrunk by 162% YoY and by 21% QoQ
The P/B is 191% above the 5-year quarterly average of 2.9 and 65% above the last 4 quarters average of 5.1
Definium Therapeutics's equity has increased by 25% YoY but it has decreased by 16% from the previous quarter

Efficiency

How efficient is Definium Therapeutics business performance
DFTX's ROA has plunged by 166% YoY and by 17% from the previous quarter
Definium Therapeutics's ROIC has decreased by 48% from the previous quarter but it has increased by 29% YoY
The ROE is down by 21% since the previous quarter

Dividends

What is DFTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DFTX.

Financial health

How did Definium Therapeutics financials performed over time
The total liabilities has soared by 133% YoY and by 14% from the previous quarter
Definium Therapeutics's total assets has increased by 46% YoY but it has decreased by 9% from the previous quarter
The debt is 85% smaller than the equity
The debt has surged by 85% year-on-year
Definium Therapeutics's debt to equity has soared by 50% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.